Track NGNE and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$613.09M
Enterprise Value$347.14M
Revenue (TTM)-
Net Income (TTM)-$90.35M
Free Cash Flow (TTM)-$77.76M
Financial Health
Cash$269.01M
Net Debt-$265.95M
Debt Ratio0.01
Debt to Equity0.01
Interest Coverage-27,529
Valuation (TTM)
Price to Sales-
Price to Earnings-6.79
EV to EBITDA-3.85
Price to Book2.31
Price to Free Cash Flow-7.88
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-16.81%
Return on Assets-37.37%
Return on Equity-15.76%
Return on Total Capital-16.81%
Return on Capital Employed-40.47%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue0.00%
Diluted EPS-30.22%
Total Debt34.05%
Capital Expenditures-11.82%
Free Cash Flow-97.13%
CAGR (3Y)
Revenue0.00%
Diluted EPS-43.48%
Total Debt63.42%
Capital Expenditures-19.05%
Free Cash Flow-99.65%
CAGR (1Y)
Revenue-100.00%
Diluted EPS-43.64%
Total Debt2.17%
Capital Expenditures46.41%
Free Cash Flow-100.00%
$36.11-$0.57|-1.58%
Last updated: Jul 22, 4:00 PM ET
52W High$43.66
52W Low$15.93
50D SMA$31.52
200D SMA$24.94
Volume130.18K
Neurogene Inc
535 W 24th Street, New York, NY, United States, 10011
IPO
2014
Employees
131
Industry
Biotechnology
Sector
Healthcare
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20262-2
0
Q2 20251-1
0
2-quarter cumulative
3 sells0 buys
Analyst Ratings
3 analysts covering
Buy67%recommend buy
Buy
2
Hold
1
Sell
0